Specialist Shortages and AD Care in Rural and Urban Areas
SOCIAL MEDIA BROADCAST TWO

Building Capacity in AD:
Early Detection, Advancements & Patient-Centered Care

Faculty

James E. Galvin, MD, MPH

Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine
Miami, FL

Chuck Vega, MD

Clinical Professor of Family Medicine UC Irvine
Irvine, CA

Program Overview

The urgent need for this program is underscored by the growing prevalence of Alzheimer's disease (AD) in the United States and the critical importance of early diagnosis for effective intervention. AD poses a significant public health challenge, affecting millions of individuals and their families, with projections indicating a substantial increase in cases in the coming years.  However, a substantial educational gap exists regarding the recognition of early signs of the disease and the proper utilization of biomarkers for timely diagnosis. This knowledge deficit results in delayed diagnoses, missed opportunities for early intervention, and increased healthcare costs. Moreover, the scarcity of specialists, particularly in rural areas, exacerbates these challenges. Therefore, a targeted program that leverages telemedicine and tele-mentoring to enhance access to education, specialized guidance, and biomarker testing coordination is essential to address these pressing issues, ensuring that individuals receive early and accurate diagnoses, paving the way for more effective management and treatment of AD.  This program is imperative not only to improve the quality of care for Alzheimer's patients and their families but also to alleviate the strain on our healthcare system. With the development of disease-modifying treatments (DMTs) newly available and others on the horizon, early diagnosis and intervention are more critical than ever. Telemedicine and tele-mentoring provide innovative solutions to bridge geographical and educational disparities, ensuring that healthcare professionals in rural and underserved areas have the knowledge and resources they need to confidently diagnose AD and utilize biomarkers effectively. By implementing this program, we can reduce patient waiting times, decrease the burden of AD on families and caregivers, and enhance the overall healthcare landscape in our communities. The urgent and unmet need for improved education and access to biomarker-based diagnosis necessitates immediate action, making this program an essential and timely initiative in our fight against AD. 

Target Audience

This educational initiative has been designed to meet the educational needs of clinicians caring for patients with AD, including primary care providers (including internal medicine, family practice, geriatric medicine), AD specialists, dementia specialists, neurologists, nurse practitioners, and physician assistants. 

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • SUMMARIZE the adverse effects of delayed AD diagnosis, particularly in underserved areas, on patients and their families.
  • DISCUSS how to utilize biomarkers in the early diagnosis of AD to provide more accurate and timely assessments.
  • ASSESS the challenges posed by the shortage of specialists in both urban and rural settings inclusive of the impact it has on access to Alzheimer's care.

Accreditation

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium CE. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher


A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Disclosures

Disclosures of Relevant Financial Relationships

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

JAMES E. GALVIN, MD, MPH
Consulting Fee (e.g., Advisory Board):
Biogen, Cognivue, Eisai., Eli Lilly, GE Healthcare, Genetech, Roche
Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): 
Cognivue

CHUCK VEGA, MD
Consulting Fee (e.g., Advisory Board): Boehringer Ingelheim

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This educational activity is supported by independent educational grants from Eisai Inc and Lilly.

Activity Credit Amount: 0.25
Credit Type: ACCME
Release: October 11, 2024
Expiration: October 11,2025